{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:15:02Z","timestamp":1783030502678,"version":"3.54.6"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.gore.2025.101676","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:34:02Z","timestamp":1736210042000},"page":"101676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ocular surface disease related to tisotumab vedotin-tftv"],"prefix":"10.1016","volume":"57","author":[{"given":"Daniella","family":"Lent-Schochet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachar","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Seagrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Paley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V.","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2025.101676_b0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.6004\/jadpro.2023.14.2.4","article-title":"Tisotumab vedotin safety and tolerability in clinical practice: managing adverse events","volume":"14","author":"Arn","year":"2023","journal-title":"J. Adv. Pract. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2025.101676_b0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"De Bono","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.101676_b0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"issue":"5","key":"10.1016\/j.gore.2025.101676_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/10600280221118370","article-title":"A review of Tisotumab Vedotin-tftv in recurrent or metastatic cervical cancer","volume":"57","author":"Heitz","year":"2023","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.gore.2025.101676_b0025","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab Vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2025.101676_b0030","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2","key":"10.1016\/j.gore.2025.101676_b0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.gore.2025.101676_b0040","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1002\/cam4.4052","article-title":"The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med."},{"issue":"18","key":"10.1016\/j.gore.2025.101676_b0045","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.gore.2025.101676_b0050","article-title":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","volume":"33","author":"Parikh","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.gore.2025.101676_b0055","unstructured":"Seagan and Genmab. TIVDAK required eye care. Published online 2024. https:\/\/www.tivdak.com\/caring-for-your-eyes\/."},{"key":"10.1016\/j.gore.2025.101676_b0060","article-title":"Case report: Concomitant use of nightly vitamin A ointment with daily PROSE wear for ocular surface disease associated with chronic Stevens-Johnson syndrome","volume":"32","author":"Shlager","year":"2023","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.gore.2025.101676_b0065","unstructured":"TIVDAK ADMINISTRATION AND DOSE MODIFICATION. https:\/\/www.tivdakhcp.com\/dosing\/."},{"issue":"8","key":"10.1016\/j.gore.2025.101676_b0070","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody\u2013drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:39:35Z","timestamp":1739842775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":14,"alternative-id":["S2352578925000013"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101676","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular surface disease related to tisotumab vedotin-tftv","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101676"}}